---
document_datetime: 2025-12-02 06:25:30
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/eladynos.html
document_name: eladynos.html
version: success
processing_time: 0.1102414
conversion_datetime: 2025-12-28 12:31:23.610184
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Eladynos

[RSS](/en/individual-human-medicine.xml/67631)

##### Authorised

This medicine is authorised for use in the European Union

abaloparatide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Eladynos](#news-on)
- [More information on Eladynos](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Eladynos is a medicine used to treat osteoporosis (a disease that makes bones fragile) in women who have been through menopause and are at increased risk of bone fractures.

This medicine contains the active substance abaloparatide.

Expand section

Collapse section

## How is Eladynos used?

Eladynos is given once daily as an injection under the skin of the lower abdomen (belly). The maximum duration of treatment with Eladynos is 18 months. Patients or their carers can inject Eladynos themselves once they have been trained to do so.

During treatment with Eladynos, the patient should take calcium and vitamin D supplements if they are not getting enough from their diet.

The medicine can only be obtained with a prescription. For more information about Eladynos, see the package leaflet or contact your doctor or pharmacist.

## How does Eladynos work?

Osteoporosis happens when not enough new bone grows to replace the bone that is naturally broken down. Gradually, the bones become thin and fragile, and more likely to fracture (break). In women, osteoporosis is more common after the menopause, when levels of the female hormone oestrogen fall.

The active substance in Eladynos, abaloparatide, is similar to part of the human parathyroid hormone. It acts like this hormone in stimulating bone formation by activating bone-forming cells called osteoblasts.

## What benefits of Eladynos have been shown in studies?

In a main study involving 2,070 patients, Eladynos was more effective than placebo (a dummy treatment) in reducing fractures in the spine in women with osteoporosis who have been through menopause.

After 18 months, 0.5% of those treated with Eladynos had a new spinal fracture compared with 4.2% in the group who received placebo.

## What are the risks associated with Eladynos?

The most common side effects with Eladynos (which may affect more than 1 in 10 people) are hypercalciuria (high calcium levels in the urine) and dizziness. Other common side effects (which may affect up to 1 in 10 people) are back pain, nausea, headache, joint pain, high blood pressure, reactions at the injection site, and palpitations (a forceful heartbeat that may be rapid or irregular). For the full list of side effects of Eladynos, see the package leaflet.

Eladynos must not be used in women who are hypersensitive (allergic) to abaloparatide or any of the other ingredients, pregnant or breastfeeding women, women who are able to have children and women with hypercalcaemia (high calcium levels in the blood), severely reduced kidney function or unexplained high levels of alkaline phosphatase (an enzyme). Eladynos must also not be used in patients at risk for osteosarcoma (a type of bone cancer) or in patients who have bone cancer or cancer that has spread to the bones.

For the full list of restrictions, see the package leaflet.

## Why is Eladynos authorised in the EU?

There is a need for new safe and effective medicines for preventing fractures in women who have been through menopause and have osteoporosis. The main study showed that Eladynos reduces the risk of spinal fractures in these patients. The results also suggest that it may reduce the risk of non-spinal fractures.

Regarding safety, the side effects of Eladynos were mostly mild to moderate. Although Eladynos can increase the heart rate after injection, there is no evidence that it causes major heart problems. As a precaution, doctors should assess the risks before starting treatment and should monitor the heart function of patients with cardiovascular disease (affecting the heart and blood circulation).

The European Medicines Agency decided that Eladynos' benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Eladynos?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Eladynos have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Eladynos are continuously monitored. Suspected side effects reported with Eladynos are carefully evaluated and any necessary action taken to protect patients.

## Other information about Eladynos

Eladynos received a marketing authorisation valid throughout the EU on 12 December 2022.

Eladynos :  EPAR - Medicine overview

Reference Number: EMA/852056/2022

English (EN) (105.26 KB - PDF)

**First published:** 22/12/2022

[View](/en/documents/overview/eladynos-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-15)

български (BG) (115.95 KB - PDF)

**First published:**

22/12/2022

[View](/bg/documents/overview/eladynos-epar-medicine-overview_bg.pdf)

español (ES) (103.75 KB - PDF)

**First published:**

22/12/2022

[View](/es/documents/overview/eladynos-epar-medicine-overview_es.pdf)

čeština (CS) (109.1 KB - PDF)

**First published:**

22/12/2022

[View](/cs/documents/overview/eladynos-epar-medicine-overview_cs.pdf)

dansk (DA) (102.12 KB - PDF)

**First published:**

22/12/2022

[View](/da/documents/overview/eladynos-epar-medicine-overview_da.pdf)

Deutsch (DE) (106.34 KB - PDF)

**First published:**

22/12/2022

[View](/de/documents/overview/eladynos-epar-medicine-overview_de.pdf)

eesti keel (ET) (92.66 KB - PDF)

**First published:**

22/12/2022

[View](/et/documents/overview/eladynos-epar-medicine-overview_et.pdf)

ελληνικά (EL) (117 KB - PDF)

**First published:**

22/12/2022

[View](/el/documents/overview/eladynos-epar-medicine-overview_el.pdf)

français (FR) (108.68 KB - PDF)

**First published:**

22/12/2022

[View](/fr/documents/overview/eladynos-epar-medicine-overview_fr.pdf)

hrvatski (HR) (105.75 KB - PDF)

**First published:**

22/12/2022

[View](/hr/documents/overview/eladynos-epar-medicine-overview_hr.pdf)

italiano (IT) (105.3 KB - PDF)

**First published:**

22/12/2022

[View](/it/documents/overview/eladynos-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (117.09 KB - PDF)

**First published:**

22/12/2022

[View](/lv/documents/overview/eladynos-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (106.54 KB - PDF)

**First published:**

22/12/2022

[View](/lt/documents/overview/eladynos-epar-medicine-overview_lt.pdf)

magyar (HU) (107.48 KB - PDF)

**First published:**

22/12/2022

[View](/hu/documents/overview/eladynos-epar-medicine-overview_hu.pdf)

Malti (MT) (109.89 KB - PDF)

**First published:**

22/12/2022

[View](/mt/documents/overview/eladynos-epar-medicine-overview_mt.pdf)

Nederlands (NL) (105.16 KB - PDF)

**First published:**

22/12/2022

[View](/nl/documents/overview/eladynos-epar-medicine-overview_nl.pdf)

polski (PL) (109.02 KB - PDF)

**First published:**

22/12/2022

[View](/pl/documents/overview/eladynos-epar-medicine-overview_pl.pdf)

português (PT) (103.74 KB - PDF)

**First published:**

22/12/2022

[View](/pt/documents/overview/eladynos-epar-medicine-overview_pt.pdf)

română (RO) (106.37 KB - PDF)

**First published:**

22/12/2022

[View](/ro/documents/overview/eladynos-epar-medicine-overview_ro.pdf)

slovenčina (SK) (108.22 KB - PDF)

**First published:**

22/12/2022

[View](/sk/documents/overview/eladynos-epar-medicine-overview_sk.pdf)

slovenščina (SL) (104.6 KB - PDF)

**First published:**

22/12/2022

[View](/sl/documents/overview/eladynos-epar-medicine-overview_sl.pdf)

Suomi (FI) (100.32 KB - PDF)

**First published:**

22/12/2022

[View](/fi/documents/overview/eladynos-epar-medicine-overview_fi.pdf)

svenska (SV) (101.23 KB - PDF)

**First published:**

22/12/2022

[View](/sv/documents/overview/eladynos-epar-medicine-overview_sv.pdf)

Eladynos : EPAR - Risk-management-plan

English (EN) (1.17 MB - PDF)

**First published:** 22/12/2022

[View](/en/documents/rmp/eladynos-epar-risk-management-plan_en.pdf)

## Product information

Eladynos: EPAR - Product information

English (EN) (755.35 KB - PDF)

**First published:** 22/12/2022

**Last updated:** 12/04/2024

[View](/en/documents/product-information/eladynos-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-137)

български (BG) (837.41 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/bg/documents/product-information/eladynos-epar-product-information_bg.pdf)

español (ES) (771.21 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/es/documents/product-information/eladynos-epar-product-information_es.pdf)

čeština (CS) (809.4 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/cs/documents/product-information/eladynos-epar-product-information_cs.pdf)

dansk (DA) (763.26 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/da/documents/product-information/eladynos-epar-product-information_da.pdf)

Deutsch (DE) (783.51 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/de/documents/product-information/eladynos-epar-product-information_de.pdf)

eesti keel (ET) (750.6 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/et/documents/product-information/eladynos-epar-product-information_et.pdf)

ελληνικά (EL) (851.12 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/el/documents/product-information/eladynos-epar-product-information_el.pdf)

français (FR) (793.35 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/fr/documents/product-information/eladynos-epar-product-information_fr.pdf)

hrvatski (HR) (819.67 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/hr/documents/product-information/eladynos-epar-product-information_hr.pdf)

íslenska (IS) (762.63 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/is/documents/product-information/eladynos-epar-product-information_is.pdf)

italiano (IT) (765.01 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/it/documents/product-information/eladynos-epar-product-information_it.pdf)

latviešu valoda (LV) (816.12 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/lv/documents/product-information/eladynos-epar-product-information_lv.pdf)

lietuvių kalba (LT) (833.47 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/lt/documents/product-information/eladynos-epar-product-information_lt.pdf)

magyar (HU) (839.07 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/hu/documents/product-information/eladynos-epar-product-information_hu.pdf)

Malti (MT) (871.54 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/mt/documents/product-information/eladynos-epar-product-information_mt.pdf)

Nederlands (NL) (773.38 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/nl/documents/product-information/eladynos-epar-product-information_nl.pdf)

norsk (NO) (750.86 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/no/documents/product-information/eladynos-epar-product-information_no.pdf)

polski (PL) (848.55 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/pl/documents/product-information/eladynos-epar-product-information_pl.pdf)

português (PT) (767.95 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/pt/documents/product-information/eladynos-epar-product-information_pt.pdf)

română (RO) (863.89 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/ro/documents/product-information/eladynos-epar-product-information_ro.pdf)

slovenčina (SK) (831.81 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/sk/documents/product-information/eladynos-epar-product-information_sk.pdf)

slovenščina (SL) (817.99 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/sl/documents/product-information/eladynos-epar-product-information_sl.pdf)

Suomi (FI) (747.05 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/fi/documents/product-information/eladynos-epar-product-information_fi.pdf)

svenska (SV) (757.53 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

12/04/2024

[View](/sv/documents/product-information/eladynos-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0008 11/04/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Eladynos : EPAR - All authorised presentations

English (EN) (36.91 KB - PDF)

**First published:** 22/12/2022

**Last updated:** 06/12/2023

[View](/en/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-153)

български (BG) (66.65 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/bg/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_bg.pdf)

español (ES) (56.76 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/es/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_es.pdf)

čeština (CS) (76 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/cs/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (57.8 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/da/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (58.66 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/de/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (34.47 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/et/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (72.89 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/el/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_el.pdf)

français (FR) (56.32 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/fr/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (64.95 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/hr/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (56.71 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/is/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_is.pdf)

italiano (IT) (55.66 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/it/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (73.72 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/lv/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (75.52 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/lt/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (73.52 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/hu/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (57.05 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/mt/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (56.05 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/nl/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (57.29 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/no/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_no.pdf)

polski (PL) (78.13 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/pl/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_pl.pdf)

português (PT) (57.17 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/pt/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_pt.pdf)

română (RO) (73.35 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/ro/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (74.26 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/sk/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (73.04 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/sl/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (55.25 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/fi/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (56.19 KB - PDF)

**First published:**

22/12/2022

**Last updated:**

06/12/2023

[View](/sv/documents/all-authorised-presentations/eladynos-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Eladynos Active substance abaloparatide International non-proprietary name (INN) or common name abaloparatide Therapeutic area (MeSH)

- Osteoporosis, Postmenopausal
- Osteoporosis

Anatomical therapeutic chemical (ATC) code H05AA04

### Pharmacotherapeutic group

Calcium homeostasis

### Therapeutic indication

Treatment of osteoporosis in postmenopausal women at increased risk of fracture.

## Authorisation details

EMA product number EMEA/H/C/005928

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Theramex Ireland Limited

3rd Floor, Kilmore House

Opinion adopted 13/10/2022 Marketing authorisation issued 12/12/2022 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Eladynos : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (105.88 KB - PDF)

**First published:** 22/05/2023

**Last updated:** 12/04/2024

[View](/en/documents/procedural-steps-after/eladynos-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Eladynos : EPAR - Public assessment report

Adopted

Reference Number: EMA/857958/2022

English (EN) (4.6 MB - PDF)

**First published:** 22/12/2022

[View](/en/documents/assessment-report/eladynos-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Eladynos

Adopted

Reference Number: EMA/806878/2022

English (EN) (99.22 KB - PDF)

**First published:** 13/10/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-eladynos_en.pdf)

#### News on Eladynos

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 October 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-october-2022) 14/10/2022

#### More information on Eladynos

- [European non-interventional post-authorization safety study (PASS) to evaluate cardiovascular (CV) events and all-cause mortality in patients newly exposed to abaloparatide or teriparatide - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000613)

**This page was last updated on** 12/04/2024

## Share this page

[Back to top](#main-content)